Teleflex Showcases Barrigel Rectal Spacer at ASTRO Meeting
Teleflex Highlights Barrigel Rectal Spacer at ASTRO Annual Meeting
Teleflex Incorporated (NYSE: TFX), a prominent provider of medical technology, is set to unveil significant findings at the upcoming American Society for Radiation Oncology (ASTRO) Annual Meeting. These presentations will showcase groundbreaking research on their Barrigel™ rectal spacer, a pioneering product designed for enhanced patient outcomes in prostate cancer radiation therapy.
Enhancing Prostate Cancer Treatment
The Barrigel™ rectal spacer is recognized as the first and only sculptable rectal spacer on the market. This innovative device utilizes Non-Animal Stabilized Hyaluronic Acid (NASHA) to create a protective barrier between the prostate and rectum, reducing undesired radiation exposure and improving the quality of life for patients undergoing treatment. Recent studies demonstrate that Barrigel can significantly reduce radiation impacting the rectum, with an impressive success rate of 98.5%. This effectiveness has made it a vital tool for clinical practices treating prostate cancer patients with stages T1-T3b disease.
Key Presentations at ASTRO
At the ASTRO Annual Meeting, which will be held from September 29 to October 2 in Washington, DC, Teleflex will feature three essential studies:
- Impact of Hyaluronic Acid (HA) Rectal Spacer Quality on Patient Outcomes: An abstract titled "Impact of Hyaluronic Acid Rectal Spacer Quality Score and Spacer Symmetry Score on Rectal Dosimetry and Acute and Late Gastrointestinal Toxicity Outcomes" will explore the quality of Barrigel's spacer and its implications on treatment-related gastrointestinal side effects.
- Rectal Wall Infiltration Protocol: Another notable presentation will discuss inadvertent rectal wall infiltration following the installation of the Barrigel™ rectal spacer. This analysis sheds light on how to manage such complications effectively.
- Feasibility of Using HA Rectal Spacer in Recurrent Cases: A study focusing on the use of Barrigel™ rectal spacer in patients with locally recurrent prostate cancer who had received previous radiation therapy reviews the safety and efficacy of the device in this challenging cohort.
Educational Symposium and Booth Activities
In addition to the presentations, Teleflex will host an educational symposium titled “The Science of Personalized Spacing” at the John F. Kennedy Center for the Performing Arts. Esteemed faculty including Dr. Peter F. Orio III and other leading physicians will lead discussions on best practices for utilizing Barrigel™ in clinical settings.
Attendees can visit Teleflex's booth (1223) during the conference where they will have a unique opportunity to observe the Barrigel™ rectal spacer procedure. Clinicians will also have access to simulations to familiarize themselves with the application of this innovative device. Notable discussions with expert clinicians are scheduled throughout the event, providing valuable insights into advanced treatments in prostate cancer care.
About Barrigel™ Rectal Spacer
Barrigel™ is specifically designed to offer a safe and effective solution for reducing rectal radiation risk during prostate cancer treatments. Its composition of NASHA ensures compatibility and absorbability in the human body, making it a trusted choice for healthcare providers. Its clinical application demonstrates a significant reduction of side effects tied to radiation therapy, making it a preferred option in multiple countries including the United States and Australia.
Teleflex continues to pioneer advancements in medical technology, with a commitment to improving patient health outcomes. The innovative work with the Barrigel™ rectal spacer is just one of many initiatives aimed at setting new standards in healthcare.
Frequently Asked Questions
What is Barrigel™ rectal spacer?
Barrigel™ is the first hyaluronic acid-based rectal spacer designed specifically to reduce radiation exposure to the rectum during prostate cancer radiation therapy.
How does Barrigel™ improve patient outcomes?
By creating a protective space between the prostate and rectum, Barrigel™ minimizes unwanted radiation exposure, significantly improving the quality of life for prostate cancer patients.
Where can I learn more about the Barrigel™ rectal spacer?
For more information, healthcare professionals can visit the official Barrigel website.
What will be presented at the ASTRO Annual Meeting regarding Barrigel™?
Three clinical studies showcasing the safety and effectiveness of Barrigel™, including its management in recurrent cases, will be highlighted at the conference.
Is Barrigel™ approved for use in other countries?
Yes, Barrigel™ rectal spacer is approved for use in the United States, Australia, and Europe for prostate cancer patients with T1-T3b disease.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Top Semiconductor Stocks to Watch Amid AI Demand Growth
- Examining Super Micro's Challenges Amid Regulatory Scrutiny
- Welshare Health's New AI App Revolutionizes Patient Research
- Septerna Initiates Promising Clinical Trial for SEP-786
- Covalon Technologies to Showcase Innovations in Vascular Access Care
- Marqeta Sets Date for Third Quarter Financial Results Call
- Celebrating Biotech Innovation: 2024 Endpoints 11 Winners Revealed
- Generate Capital Welcomes New Leaders to Drive Growth and Impact
- Major Attendance at Shincheonji Church's Impactful Seminar
- Boston Scientific's Innovative FARAPULSE System Gains Approval
Recent Articles
- Hut 8 Launches GPU-as-a-Service to Boost AI Capabilities
- Hut 8's GPU Service Launch: Revolutionizing AI Compute Power
- ForFarmers Enhances Commitment to Sustainable Agricultural Practices
- EnGene's Detalimogene Shows Promising Efficacy in Bladder Cancer
- KalVista Pharmaceuticals Showcases Nine Abstracts at Global Forum
- Telesis Bio Soars 110% in Premarket Trading: Key Insights
- Henry Schein Launches Prepare to Care Initiative for Health Relief
- Arizona Sonoran Elevates Nick Hayduk to Key Corporate Role
- REE Automotive's Strategic Moves Propel Growth in EV Sector
- Clean Energy Fuels Sets New Standard with CNG Station
- Ispire Technology Inc.: A Strong Growth Year and Future Plans
- Clean Energy to Establish Innovative CNG Station for METRO
- Mendel AI Unveils Game-Changing Hypercube Platform for Healthcare
- PureTech Systems Secures Major Contract for AI Maritime Security
- Micron's Earnings Spark Tech Optimism Amid Market Shifts
- Vantage Foundation Boosts Youth Support with Metta Home Partnership
- BeiGene Welcomes Shalini Sharp to Board for Financial Growth
- Understanding IRS Audits: Civil vs. Criminal Proceedings
- Lulus Expands Distribution Through Dillard's Partnership
- Patterson-UTI Energy Faces Headwinds While Simplifying Strategy
- JPMorgan Affirms Overweight Rating on Braze Inc Stock
- Jefferies Group Stock Update: Strong Performance and Future Prospects
- monday.com Achieves Key Growth Milestones Amid Analyst Praise
- Strengthening Chinese Banks: Essential for Economic Recovery
- China to Bolster Economy with Major Sovereign Bond Issuance
- Guardian Pharmacy Announces Successful $14/share IPO Launch
- Challenges Ahead for European Stocks Tied to China’s Economy
- Analyzing Shifting Dynamics in Cryptocurrency Markets Today
- The Race to the Moon: New Opportunities for Investors
- AI Optimism Fuels Stock Market Rally as Investors React
- Understanding Daily Fund Prices for WisdomTree ETFs
- Clean Motion Launches Solar-Powered EVIG Pilot for Healthcare Delivery
- Revitalizing the Pomegranate Industry: A New Era Unveiled
- Elon Musk's Bold Demand for FAA Chief Mike Whitaker's Exit
- Adjustments to Floating-Rate Bonds Coupons by Nykredit
- SpaceX Eyes $1.5B Boost for Starlink Services in Vietnam
- Bybit's WSOT 2024 Livestream: Champions, Insights, Giveaways
- Emerging Trends in Personal Emergency Response Systems
- Sunny Lowe Joins Prime Mining's Board of Directors Bringing Expertise
- Titan Mining Welcomes Rita Adiani as New President to Lead Growth
- Centessa Pharmaceuticals Showcases Innovative Orexin Agonist Data
- Tri Pointe Homes, Inc. Set for Important Q3 Earnings Call
- Fortis Inc. Unveils $26 Billion Capital Strategy and Dividend Boost
- Exploring the Breakthrough of CD47 Immunotherapy in Cancer Treatment
- DPC Dash Reports Strong Growth in 2024 Interim Results
- Intelligent Communication Forum 2024: A Global Spotlight
- Balancing Act: Tech Stocks Amidst ESG Challenges and Opportunities
- Shining a Light on the 2024 China International Forum
- Elevate Your Home Atmosphere with Toshiba's Latest TVs
- Stock Ratings Shift: Challenges Ahead for Hershey Company